NCT03602781View on ClinicalTrials.gov

Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2018

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2020

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Placebo

Placebo at a dose setting of 75 mcg/kg IBW/hr

DRUG

iNO

iNO at a dose setting of 75 mcg/kg IBW/hr

Trial Locations (4)

29425

Medical University of South Carolina, Charleston

60611

Bluhm Cardiovascular Institute, Clinical Trials Unit, Chicago

T1Y6J4

Peter Lougheed Centre, Calgary

M5G 2C4

Toronto General Hospital, University Health Network, Toronto

Sponsors

Collaborators (1)

Worldwide Clinical Trials
All Listed Sponsors
collaborator

Worldwide Clinical Trials

OTHER

lead

Bellerophon Pulse Technologies

INDUSTRY